Results 1 to 10 of about 9,097,693 (196)

SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets

open access: yesGenomics, Proteomics & Bioinformatics, 2022
Combinatorial therapies have been recently proposed to improve the efficacy of anticancer treatment. The SynergyFinder R package is a software used to analyze pre-clinical drug combination datasets.
Shuyu Zheng   +7 more
doaj   +4 more sources

The recent progress of deep-learning-based in silico prediction of drug combination

open access: yesDrug Discovery Today, 2023
Drug combination therapy has become a common strategy for the treatment of complex diseases. There is an urgent need for computational methods to efficiently identify appropriate drug combinations owing to the high cost of experimental screening.
Ting Ran, Yuedong Yang, Zhiguang Fan
exaly   +2 more sources

Machine learning approaches for drug combination therapies

open access: yesBriefings in Bioinformatics, 2021
Drug combination therapy is a promising strategy to treat complex diseases such as cancer and infectious diseases. However, current knowledge of drug combination therapies, especially in cancer patients, is limited because of adverse drug effects ...
Hiroshi Mamitsuka, Samuel Kaski
exaly   +2 more sources

Predicting drug combination response surfaces. [PDF]

open access: yesNPJ Drug Discov
Prediction of drug combination responses is a research question of growing importance for cancer and other complex diseases. Current machine learning approaches generally consider predicting either drug combination synergy summaries or single combination
Huusari R   +4 more
europepmc   +2 more sources

Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations

open access: yesCancers, 2021
Simple Summary Chemotherapy is a key modality in today’s practice of clinical oncology. The potential for systemic treatment of cancer patients with cytotoxic agents was discovered in the mid 20th century and its major shortcomings namely, off target ...
Gary Gellerman   +2 more
exaly   +2 more sources

Formononetin: a review of its source, pharmacology, drug combination, toxicity, derivatives, and drug delivery systems

open access: yesFrontiers in Pharmacology
Formononetin (FMN) is a common natural metabolite that can be extracted and isolated from some common botanical drugs. In recent years, FMN has garnered increasing attention due to its beneficial biological activities.
Min Jin   +12 more
doaj   +3 more sources

Improving synergistic drug combination prediction with signature-based gene expression features in oncology [PDF]

open access: yesFrontiers in Pharmacology
BackgroundCombination therapies play a crucial role in the treatment of complex diseases, such as cancer. They enhance efficacy, minimize resistance, and reduce toxicity by leveraging synergistic effects.
Mozhgan Mozaffarilegha   +1 more
doaj   +2 more sources

Novel Developments to Enable Treatment of CNS Diseases with Targeted Drug Delivery

open access: yesPharmaceutics, 2023
The blood-brain barrier (BBB) is a major hurdle for the development of systemically delivered drugs against diseases of the central nervous system (CNS).
Axel H. Meyer   +5 more
doaj   +1 more source

Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review

open access: yesFrontiers in Endocrinology, 2023
Diabetes is a chronic metabolic disease, and its therapeutic goals focus on the effective management of blood glucose and various complications. Drug combination therapy has emerged as a comprehensive treatment approach for diabetes. An increasing number
Xue-Qin Xie   +10 more
semanticscholar   +1 more source

Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy

open access: yesMicroorganisms, 2023
Influenza infection is serious and debilitating for humans and animals. The influenza virus undergoes incessant mutation, segment recombination, and genome reassortment.
Sania Batool   +2 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy